QOL MEDICAL, LLC DISCONTINUES SPONSORSHIP OF THE ¹³C-SUCROSE BREATH TEST PROGRAM EFFECTIVE MARCH 1, 2025
VERO BEACH, Fla., Feb. 19, 2025 /PRNewswire/ -- QOL Medical, LLC, a ground-breaking rare disease pharmaceutical company, has announced that it will no longer sponsor the 13C-sucrose breath test program, which was previously offered free of charge to patients presenting with symptoms of Congenital Sucrase-Isomaltase Deficiency (CSID). This change will take effect on March 1, 2025.
Congenital Sucrase-Isomaltase Deficiency (CSID) is largely a clinical diagnosis that requires a thorough review of the patient's medical history. While there are several tests available to aid in diagnosing CSID, the breath test remains an important diagnostic tool.
Following this change, the 13C-sucrose breath test will still be available through Metabolic Solutions, but patients and/or their insurance will now be responsible for covering the cost of the test.
For any questions about the 13C-sucrose breath test, including details on reimbursement, patients and healthcare providers are encouraged to contact Metabolic Solutions directly.
Contact information for Metabolic Solutions:
- Phone: 603-598-6960
- Email: info@metsol.com
QOL Medical remains committed to improving quality of life for patients and thanks everyone for their understanding of this transition.
About CSID
People with CSID, commonly known as sucrose (sugar) intolerance, are unable to properly digest sucrose (table sugar), which is found in foods like ice cream, apples, cake, and corn. In adolescents and adults, CSID has been characterized by symptoms of chronic abdominal pain, gas, bloating, and diarrhea, which overlap with common irritable bowel syndrome (IBS) symptoms. In infants, CSID classically presents as explosive watery diarrhea, failure to thrive, diaper rash, irritability, and acidic stools.
About QOL Medical, LLC
QOL Medical is a specialty biopharmaceutical company committed to delivering rare solutions for rare diseases—driven by you. Founded in 2003, QOL Medical focuses on improving clinical outcomes and enhancing the quality of life for patients with rare diseases through the acquisition and commercialization of orphan and gastrointestinal products in underserved markets. Learn more at www.qolmed.com.
Media Contact:
QOL Medical, LLC
Tiffany Carter
Phone: 818-720-8557
Email: tiffany@tlcmarketingpr.com
Corporate Contact:
QOL Medical, LLC
3405 Ocean Drive
Vero Beach, FL 32963
Phone: 866-469-3773
Fax: 772-365-3375
Email: info@qolmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/qol-medical-llc-discontinues-sponsorship-of-the-c-sucrose-breath-test-program-effective-march-1-2025-302379572.html
SOURCE QOL Medical, LLC